Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 16/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.53 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6598891 | 0.88 | OPRD1 (0.58) | OPRD1OPRK1OPRM1 | |
| SCHEMBL6598384 | 0.83 | OPRD1 (0.76) | OPRD1OPRK1OPRM1 | |
| SCHEMBL6595690 | 0.82 | OPRD1 (0.79) | OPRD1OPRK1OPRM1 | |
| SCHEMBL7198825 | 0.79 | OPRD1 (0.53) | OPRD1OPRK1OPRM1 | |
| SCHEMBL5879390 | 0.77 | OPRD1 (0.62) | OPRD1OPRK1OPRM1 | |
| SCHEMBL1996254 | 0.75 | OPRD1 (0.60) | OPRD1OPRK1OPRM1 | |
| SCHEMBL6598904 | 0.75 | OPRD1 (0.75) | OPRD1OPRK1OPRM1 | |
| SCHEMBL7198445 | 0.74 | OPRD1 (0.69) | OPRD1OPRK1OPRM1 | |
| SCHEMBL6599265 | 0.73 | OPRD1 (0.59) | OPRD1OPRK1OPRM1 | |
| SCHEMBL6598126 | 0.72 | OPRD1 (0.58) | OPRD1OPRK1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140835-B1 | 3,3-BIARYLPIPERIDINE AND 2,2-BIARYLMORPHOLINE DERIVATIVES | PFIZER PROD INC (US) | 2004-05-12 | — | — | EP | disclosed |
| US-20040063940-A1 | 3,3-Biarylpiperidine and 2,2-biarylmorpholine derivatives | PFIZER INC | 2004-04-01 | — | — | US | disclosed |
| US-6586431-B1 | Treating drug abuse and drug dependence; nervous system and gastrointestinal disorders | PFIZER INC | 2003-07-01 | — | — | US | disclosed |
| US-6503905-B1 | Treating nervous system and gastrointestinal disorders; analgesics, antiasthmatics | PFIZER INC | 2003-01-07 | — | — | US | disclosed |
| CN-1332727-A | 3, 3-diarylpiperidine and 2, 2-diarylmorpholine derivatives | PFIZER PROD INC (US) | 2002-01-23 | — | — | CN | disclosed |
| EP-1140835-A1 | 3,3-BIARYLPIPERIDINE AND 2,2-BIARYLMORPHOLINE DERIVATIVES | Pfizer Products Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039091-A1 | 3,3-BIARYLPIPERIDINE AND 2,2-BIARYLMORPHOLINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063940-A1 | 3,3-Biarylpiperidine and 2,2-biarylmorpholine derivatives | BCHE, HTR3C, CHRM2 | OPRD1 24/4885OPRK1 39/4885OPRM1 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.